India's Gland Pharma posts quarterly profit fall, hit by sluggish U.S. sales

Gland Pharma

20/05/2025 12:46

Adds chart; no changes to text

May 20 (Reuters) - India's Gland Pharma GLAD.NS, which make injectable versions of generic drugs, reported a 3.1% fall in fourth-quarter profit on Tuesday, weighed down by weaker sales in the U.S., a key region for the company.

The company reported a consolidated net profit of 1.87 billion rupees ($21.9 million) for the quarter ended March 31, compared with 1.92 billion rupees in the year-ago quarter.

Revenue from operations slipped 7.3% to 14.25 billion rupees. Sales from U.S. business, which accounts for 54% of the total, fell 10%.

For further results highlights, click (Full Story)

KEY CONTEXT

Production setbacks at Cenexi's facilities in Paris and Belgium for the past two quarters have been weighing on the company's earnings.

Most of India's generic drugmakers derive a significant share of revenue from the United States, where lower drug prices due to stiff competition have been weighing on earnings.

Rivals Sun Pharma SUN.NS and Cipla CIPL.NS and Dr Reddy's REDY.NS beat fourth-quarter profit estimates.

PEER COMPARISON

Valuation (next 12 months)
Estimates (next 12 months)
Analysts' sentiment
RIC
PE
EV/EBITDA
Price/Sales
Revenue growth (%)
Profit growth (%)
Mean rating*
No. of analysts
Stock to price target**
Div yield (%)
Gland Pharma
GLAD.NS
24.59
13.42
NULL
12.43
33.07
Hold
10
0.91
1.36
Zydus Lifesciences
ZYDU.NS
19.60
13.33
3.81
6.10
-1.22
Hold
27
0.87
0.33
Cipla
CIPL.NS
23.43
15.27
3.69
6.95
-3.45
Buy
33
0.91
0.87
Dr Reddy's Laboratories
REDY.NS
17.24
11.36
3.10
6.97
0.92
Hold
35
0.96
0.65

 * Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell
 ** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

JANUARY TO MARCH STOCK PERFORMANCE

-- All data from LSEG

-- $1 = 85.5650 Indian rupees

($1 = Indian rupees)

GLAND PHARMA JAN-MARCH https://tmsnrt.rs/45hVRzH

 (Reporting by Yagnoseni Das in Bengaluru)

 ((Yagnoseni.Das@thomsonreuters.com;))